.png){kind=icon}
.png){kind=icon}
Return
Hepatobiliary Cancers, Version 2.2021
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2021.0022.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepa-tocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatol-ogists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer ex-pertise. In addition to surgery, transplant, and intra-arterial thera-pies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezo-lizumab and bevacizumab became the first regimen to show superi -or survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.
Keywords:
UNRESECTABLE HEPATOCELLULAR-CARCINOMA
RANDOMIZED CONTROLLED-TRIAL
BODY RADIATION-THERAPY
PHASE-II TRIAL
DOXORUBICIN-ELUTING BEADS
PORTAL-VEIN EMBOLIZATION
CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION
PERCUTANEOUS RADIOFREQUENCY ABLATION
CLASSIFYING MICROVASCULAR INVASION
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations